This review highlights silica nanoparticles' role in regulating amyloid protein aggregation, suggesting therapeutic potential.
The aggregation and deposition of amyloid proteins are considered key contributors to the pathogenesis of various diseases. In recent years, a variety of nanoparticles have been employed to modulate amyloid protein aggregation. Among them, silica nanoparticles (SNs) have emerged as particularly promising due to the excellent biocompatibility of silicon-based materials and their favorable physicochemical properties, offering significant therapeutic potential. This review summarizes recent studies on the use of SNs to regulate the aggregation of amyloid proteins. The effects of different types and surface-modified SNs on the aggregation behavior of various amyloid proteins are systematically compared, aiming to provide valuable insights for future research and potential therapeutic applications.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: